Europe Colorectal Cancer Screening Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Europe Colorectal Cancer Screening Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Certain factors that are driving the Eurpean colorectal cancer screening market growth include the advent of efficacious genetic tests, a growing burden of colorectal cancer, and increasing cancer prevention initiatives. According to the WHO (World Health Organization), in Europe, colorectal cancer is considered the second-most common cause of cancer death in men and women. It is the second-most common form of cancer in women, after breast cancer, and the third-most common in men, after lung and prostate cancers.

There exist several screening options for the early detection of colorectal cancer. These include flexible sigmoidoscopy, fecal occult blood test (FOBT), colonoscopy, and computed tomographic colonography. The European Union recommends FOBT screening for colorectal cancer in men and women of age between 50 and 74. Owing to the fact that colorectal cancer risk varies across Europe, the benefit of screening is also expected to vary. However, with a high-quality screening program and sufficient participation, mortality reduction can be anticipated in all countries.

The guaiac fecal occult blood test (gFOBT) is one of the several methods that is used to detect colorectal cancer. The test involves the detection of hidden blood in the feces and identifies the presence of cancer cells or tumors in the colon or rectum. The test involves placing a small sample of stool on specially guaiac coated cards and then sent to a laboratory for testing. Upon putting a testing solution on the cards, the guaiac causes the stool sample to change color. The color changes very quickly, if there is blood in the stool. The presence of blood in the stool may be a sign of colorectal cancer or other problems, such as polyps, ulcers, or hemorrhoids. However, the factors that are driving the market are its ease of availability, low cost, and coverage in the insurance, along with being sold as over-the-counter. Additionally, with product innovation, the method has become reliable. The growth of the market is mainly attributed to the ease of availability and low cost of the products.

The European colorectal cancer screening market is highly competitive and consists of a number of major players. Companies, like Abbott Laboratories, Epigenomics Inc., Exact Sciences Corporation, F. Hoffmann-La Roche AG, Novigenix SA, Quidel Corporation, Siemens Healthcare Private Limited, and Sysmex Corporation, among others, hold substantial share in the market studied.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support